Dr. Lindsay Rosenwald – Know More About Him

Several of Dr. Rosenwald’s other companies in which he founded have became headline makers because of the treatment advances they have made. Among those companies are Sypress Biosciences with their Savella, useful in the treatment of fibromyalgia and another breakthrough from the same company is the Prosorba Column, used to treat severe rheumatoid arthritis. Other advancements from other companies in Dr. Lindsay Rosenwald’s portfolio include Trisinox developed by Polarx, it is used in acute leukemia cases; Peramivir, a vaccine for H1N1 influenza that has worldwide approval for treatment , it is from Biocryst Pharmaceuticals; and there is Titan Pharmaceuticals with its Fanapt for schizophrenia treatment ; other companies in the portfolio have developed anti-obesity drug that is breakthroughs the biggest obesity treatment breakthrough in the past thirty years and other achievements. These advancements are so important because of the seriousness of the ailments that these drugs and devices are used for. many people have found great benefit from them and had relief of their suffering.

Dr. Lindsay Rosenwald is not only known for his founding of these breakthrough biotechnology companies, but for his giving to make possible even more breakthroughs. He is a very active philanthropist distributing his giving among many venues. His Rosenwald Foundation helps by donating to institutions that educate and do research in the biotechnology and pharmaceutical fields.

Dr. Rosenwald is the current director of the Paramount Group as well as several other companies both privately owned and public. These include Neose Technologies Inc., Interneuron Pharmaceuticals Inc., and Keryx Inc. In addition to these roles he also holds    positions as a member of the board of directors for the Jewish Republican Coalition as well as having a seat on the Columbia-Presbyterian Health Sciences Advisory Council.  The Jewish Republican Coalition aims to connect the Jewish population in America with the Republican officeholders so that there will be a greater understanding and working together between them. His advisory seat enables Dr. Rosenwald to help Columbia University College of Physicians and Surgeons with his input in important decisions. Dr. Rosenwald is able to partake in very influential and important issues concerning peoples health and welfare by the many ways he gives to society.

Dr. Lindsay Rosenwald has helped many people in not only America, but the world over by his generosity and financial services. His Paramount Biocapital has helped many biotechnical companies launch out and succeed in their endeavors. From his time in private practice and thru even today he is making a difference in lives everywhere by his investments in companies and philanthropical giving.

Paramount Bio Sciences, LLC, a worldwide pharmaceutical growth and wellness
care expenditure corporation, was founded and managed by Dr. Lindsay Rosenwald
in 1991. The firm facilitates drug development, scientific assistance and dedicates
itself to finding and creating novel therapeutic medicines with large potential. By
assessing promising drug candidates throughout the world, Paramount continues
to be able to develop, nurture, and assistance additional than 40 lifestyle sciences
organizations, academic centers, biotechnology and pharmaceutical firms more than
the past 19 many years, which includes 20 from the last 48 months. Present Portfolio
Businesses have more than 40 item candidates advancing by means of clinical trials.
Exclusive method to bio tech expenditure: Enterprise and product development are
just two pieces within the extremely important puzzle. An affiliate of Important Bio
Sciences – Important Bio Budget, Inc., is usually a FINRA registered broker-dealer
that, between other actions, raises money with the Important Profile Businesses. It
raised over $1 billion for that Portfolio Organizations; several occasions that quantity
may be raised for Important Organizations by other entities. Although venture budget
and personal equity firms tend to become investment-oriented, Paramount’s bias is
within the operational side.

It establishes businesses in the ground up, employing its very own budget and at
some point funds raised from diverse personal and institutional investors by means
of Important Bio Sciences and also other banks and broker-dealers on Wall Street.
Surely, Paramount’s practical knowledge in finance and organization locations allows
make the design appealing to prospective licensors and chief executive officers.
With Vital Capital Lindsay Rosenwald mostly handling accounting, financial,
market analytical and legal functions, managers of its Profile Businesses can focus
largely on driving drug candidates as a result of the clinic and creating value for
shareholders, licensors and also the patient community.

Infrastructure and Organization Building at Very important: Important involves an
extensive help infrastructure with encounter in licensing, clinical advancement,
corporate operations, and navigating regulatory pathways. Every single new profile
business at extremely important Bio Sciences is built all-around intriguing science
and commercial prospective. The Profile Organizations are operated by Important
Budget through a dedicated first-class management at the business level, as
nicely as a result of business and clinical advancement and operations specialists
functioning for Very important in New York. Chelsea Therapeutics, for example,
initially was developed or founded by Dr. Lindsay Rosenwald approximately a
novel anti-folate becoming designed for your remedy of inflammatory ailments
that integrated rheumatoid arthritis (RA) and psoriasis. Chelsea’s compound, CH-
1504, has demonstrated superiority in terms of both safety and efficacy more than
Methotrexate, the latest treatment regular for RA, which may be identified to elevate
liver enzymes in quite a few sufferers. Important Budget licensed this technology on
the University of South Alabama and assembled a world-class management team to
help optimize its formulation and advance the growth of this along with compounds.

Lindsay Rosenwald started his professional research at Pennsylvania State University in 1973 after graduating from Abington High School. He excelled an enterprise and was particularly intrigued with economics and finance.

In quest for his lifelong dream, Rosenwald entered Temple University’s University of Medicine. After graduating from Temple University in 1983, he began an internship at Abington Hospital before starting his own private practice. After filling out his internship, he worked as a health-care professional in his very own practice for 2.5 years. Even though he cherished being a medical doctor, Rosenwald preferred a career where he could blend his two loves – medical science and business enterprise.

httpv://www.youtube.com/watch?v=H2NaRLw5mE0

Rosenwald quit his private practice in 1986 to go to Wall Street where he took on a position as a Physician / Analyst, an extremely exclusive position with just a few people doing it at that time. Despite the belief that doctors don’t make good investors, Dr Rosenwald excelled at this position. He had a passion for improving investment finance open to the health care sector and that is primarily why he worked there. People admired him and respected his opinions and knowledge. Even though he missed treating individuals, he recognized this was exactly where he belonged. During this time, he also worked for DH Blair and Company, a private investment organization, as the managing director of corporate finance. Over time, he left D.H. Blair and Company to pay attention to a new venture and firm.

In 1991, Lindsay Rosenwald founded Paramount Biotech. Over time, he has broadened this company by starting new companies and attaining control of other biotech companies. The organization has financed more than two dozen companies within the last three years. He creates these companies by concentrating on the growth of both the corporate and biotechnology portions. Paramount Capital is a conglomerate of firms including: Paramount biosciences,Paramount Corporate Development and Paramount BioCapital. All of these firms are separate entities, but interact to support one another. The firms that Rosenwald handles have licensed or acquired over a hundred experimental stage drugs.

One of the most notable accomplishments for Lindsay Rosenwald is setting the record for the speediest acceptance of a new drug to market. In merely thirty months, Arsenic Trioxide was created and approved by the FDA for the treatment of a deadly form of leukemia. This drug has been in the marketplace around the world for over ten years and has saved and prolonged 1000s of lives.

Rosenwald has created really groundbreaking companies one of his companies sold to J&J for more than One Billion Dollars even though they only had 1 drug with phase 2 data. He has also founded the very first publicly traded stem cell company, gene therapy company, and cancer vaccine company. As Rosenwald as the leader, his firms have created probably the most valuable and groundbreaking drug treatments of the 21st century. To add to his achievements he comes up with the very first successful medicine to aid those who are obese.

One of the reasons that Rosenwald’s companies have been profitable is that he hires PhDs, MDs, MBAs, and other experts to serve as his senior level professionals. These people usually have experience in business, however they also tend to possess vast knowledge in the medical community. They are driven to produce new drugs as soon as possible. Some of these medicines have the possibility to change the way we look at medical care entirely today. He has also created the Rosenwald Foundation that has contributed millions of dollars to healthcare and science instruction to help create the future of medicine.

Lindsay Rosenwald has built his business by constantly looking towards the future and now is no different. He speculates that over the next 20 years the biotech industry will continue to enlarge exponentially. Rosenwald predicts that major biotech breakthroughs of the future will come from smaller, startup biotech companies instead of the massive biotech firms we see these days. He feels the two most pressing problems we face today are heart disease and cancer.